Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で176.03%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 68.52Mに達しています。
黒字転換
同社は黒字転換を果たし、最新の年間純利益はUSD 1.46Mです。%!(EXTRA int=2)
割安
同社の最新のPEは117.14で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は234.11K株で、前四半期比で70.04%減少しています。